172 related articles for article (PubMed ID: 34680929)
1. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680929
[TBL] [Abstract][Full Text] [Related]
2. CD276 as a Candidate Target for Immunotherapy in Medullary Thyroid Cancer.
Hińcza-Nowak K; Kowalik A; Walczyk A; Pałyga I; Gąsior-Perczak D; Płusa A; Kopczyński J; Chrapek M; Góźdź S; Kowalska A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373167
[TBL] [Abstract][Full Text] [Related]
3. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Del Rivero J; Donahue RN; Marté JL; Gramza AW; Bilusic M; Rauckhorst M; Cordes L; Merino MJ; Dahut WL; Schlom J; Gulley JL; Madan RA
Front Endocrinol (Lausanne); 2020; 11():490. PubMed ID: 32849281
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Immune Profiling of Medullary Thyroid Cancer.
Pozdeyev N; Erickson TA; Zhang L; Ellison K; Rivard CJ; Sams S; Hirsch FR; Haugen BR; French JD
Thyroid; 2020 Sep; 30(9):1263-1279. PubMed ID: 32242507
[No Abstract] [Full Text] [Related]
5. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
9. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
[TBL] [Abstract][Full Text] [Related]
10. Histopathology of C Cells and Medullary Thyroid Carcinoma.
Schmid KW
Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
[TBL] [Abstract][Full Text] [Related]
11. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
12. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
13. CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
Werner TA; Forster CM; Dizdar L; Verde PE; Raba K; Schott M; Knoefel WT; Krieg A
Br J Cancer; 2017 Dec; 117(12):1837-1845. PubMed ID: 29112684
[TBL] [Abstract][Full Text] [Related]
14. Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?
Fonseca L; Freitas C; Caramelo A; Eloy C
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00241. PubMed ID: 34277966
[TBL] [Abstract][Full Text] [Related]
15. Molecular signatures of medullary thyroid carcinoma by matrix-assisted laser desorption/ionisation mass spectrometry imaging.
Smith A; Galli M; Piga I; Denti V; Stella M; Chinello C; Fusco N; Leni D; Manzoni M; Roversi G; Garancini M; Pincelli AI; Cimino V; Capitoli G; Magni F; Pagni F
J Proteomics; 2019 Jan; 191():114-123. PubMed ID: 29581064
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.
Karagiannis AK; Girio-Fragkoulakis C; Nakouti T
Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480
[TBL] [Abstract][Full Text] [Related]
17. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review.
Trimboli P; Guidobaldi L; Bongiovanni M; Crescenzi A; Alevizaki M; Giovanella L
Diagn Cytopathol; 2016 Jan; 44(1):45-51. PubMed ID: 26481456
[TBL] [Abstract][Full Text] [Related]
18. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
19. Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Shi X; Yu PC; Lei BW; Li CW; Zhang Y; Tan LC; Shi RL; Wang J; Ma B; Xu WB; Wang X; Hu JQ; Huang NS; Wei WJ; Wang Y; Chen TZ; Wang YL; Ji QH
Thyroid; 2019 Sep; 29(9):1269-1278. PubMed ID: 31328653
[No Abstract] [Full Text] [Related]
20. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]